Therefore, pharmacologic inhibition of vascular endothelial growth factor-A (VEGF-A) via targeted monoclonal antibody therapy has become the front line treatment for this blinding disease; this approach has high efficacy against AMD.3,4 Several other modalities of VEGF-A–targeted therapies have been investigated including posttranscriptional gene silencing via small interfering RNA (siRNA), an approach that showed great promise in preclinical studies. This evidence concerns the gene VEGFA and age-related macular degeneration.